BOAN BIOTECH(06955.HK)

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd.